WILEX is a biopharmaceutical company and develops drugs based on antibodies
and small molecules with a low side effect profile and targeted treatment of
different types of cancer as well as diagnostic agents for specific detection
of tumours. WILEX’ aim is to help oncologists administer targeted treatments
to carefully diagnosed patients and to enhance patients' quality of life.
07.11.2013: WILEX regains US rights for RENCAREX® from Prometheus. WILEX
AG and Prometheus Laboratories Inc., San Diego, CA, USA, agreed as of 31 October
2013 on the terms of the termination of the 2011 license agreement on RENCAREX®
(Girentuximab). ... More.
Seite gelesen: 83655 | Heute: 218